{"id":53343,"date":"2026-01-08T13:53:30","date_gmt":"2026-01-08T05:53:30","guid":{"rendered":"https:\/\/flcube.com\/?p=53343"},"modified":"2026-01-08T13:53:31","modified_gmt":"2026-01-08T05:53:31","slug":"pfizer-partners-with-cartography-on-850-million-tumor-antigen-discovery-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53343","title":{"rendered":"Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal"},"content":{"rendered":"\n<p><strong>Pfizer Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>)<\/strong> and <strong>Cartography Biosciences, Inc.<\/strong> announced a <strong>strategic collaboration<\/strong> to discover <strong>tumor-selective antigens<\/strong> using Cartography\u2019s proprietary <strong>ATLAS and SUMMIT platforms<\/strong>. Under the multi-year agreement, Pfizer may opt in on validated antigens and will lead all research, development, and commercialization. The deal, valued at up to <strong>USD\u202f850\u202fmillion<\/strong>, includes <strong>USD\u202f65\u202fmillion<\/strong> in upfront and near-term payments plus tiered royalties.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-collaboration-overview\">Collaboration Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Pfizer Inc. (NYSE: PFE), Cartography Biosciences, Inc.<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>ATLAS and SUMMIT antigen discovery platforms<\/td><\/tr><tr><td><strong>Focus<\/strong><\/td><td>Tumor-selective antigens for undisclosed indication<\/td><\/tr><tr><td><strong>Pfizer Role<\/strong><\/td><td>Opt-in on identified antigens; R&amp;D and commercialization<\/td><\/tr><tr><td><strong>Cartography Role<\/strong><\/td><td>Platform application; antigen identification and validation<\/td><\/tr><tr><td><strong>Financial Value<\/strong><\/td><td>Up to <strong>USD\u202f850\u202fmillion<\/strong><\/td><\/tr><tr><td><strong>Upfront\/Near\u2011Term<\/strong><\/td><td><strong>USD\u202f65\u202fmillion<\/strong> (payment, milestones, options)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered royalties on net sales<\/td><\/tr><tr><td><strong>Cartography Lead Program<\/strong><\/td><td>CBI\u20111214 (wholly owned, independently advanced)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-atlas-amp-summit-platforms\">Technology Profile: ATLAS &amp; SUMMIT Platforms<\/h2>\n\n\n\n<p><strong>ATLAS Platform<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High\u2011throughput screening<\/strong> of tumor vs. normal tissues to identify <strong>selectively expressed antigens<\/strong><\/li>\n\n\n\n<li><strong>Multi\u2011omics integration<\/strong>: Transcriptomics, proteomics, and spatial biology<\/li>\n\n\n\n<li><strong>Validation<\/strong>: Functional characterization in patient\u2011derived models<\/li>\n<\/ul>\n\n\n\n<p><strong>SUMMIT Platform<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Epitope mapping<\/strong> and <strong>immunogenicity prediction<\/strong> for discovered antigens<\/li>\n\n\n\n<li><strong>AI\u2011driven<\/strong> antibody engineering for optimal target engagement<\/li>\n<\/ul>\n\n\n\n<p><strong>Competitive Edge<\/strong>: Enables <strong>precision antigen targeting<\/strong> with reduced off\u2011tumor toxicity, addressing a <strong>key bottleneck<\/strong> in cancer immunotherapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-tumor-antigen-discovery\">Market Opportunity: Tumor Antigen Discovery<\/h2>\n\n\n\n<p><strong>Global Oncology Immunotherapy Market<\/strong>: <strong>$180\u202fbillion<\/strong> (2025), growing at <strong>12% CAGR<\/strong>. <strong>Tumor\u2011specific antigens<\/strong> are the <strong>next frontier<\/strong> for <strong>CAR\u2011T, TCR\u2011T, and bispecific antibodies<\/strong>.<\/p>\n\n\n\n<p><strong>Addressable Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted Therapies<\/strong>: <strong>$45\u202fbillion<\/strong> (precision oncology)<\/li>\n\n\n\n<li><strong>Cell Therapy<\/strong>: <strong>$25\u202fbillion<\/strong> (requires tumor\u2011selective targets)<\/li>\n\n\n\n<li><strong>Bispecifics<\/strong>: <strong>$35\u202fbillion<\/strong> (dependency on validated antigens)<\/li>\n<\/ul>\n\n\n\n<p>Each validated antigen could unlock <strong>$2\u20115\u202fbillion<\/strong> in therapeutic value across multiple modalities.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p><strong>For Pfizer<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Replenishment<\/strong>: Post\u2011Ibrance patent cliff drive need for <strong>novel oncology assets<\/strong><\/li>\n\n\n\n<li><strong>Platform Access<\/strong>: Cartography\u2019s technology <strong>de\u2011risks target selection<\/strong> for <strong>cell therapy and ADC programs<\/strong><\/li>\n\n\n\n<li><strong>Cost Efficiency<\/strong>: In\u2011licensing at <strong>discovery stage<\/strong> reduces per\u2011asset cost vs. <strong>$1\u20112\u202fbillion<\/strong> internal discovery<\/li>\n<\/ul>\n\n\n\n<p><strong>For Cartography<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Non\u2011Dilutive Funding<\/strong>: <strong>USD\u202f65\u202fmillion<\/strong> finances platform expansion and CBI\u20111214 development<\/li>\n\n\n\n<li><strong>Validation<\/strong>: Pfizer partnership <strong>credibility<\/strong> attracts additional pharma partners<\/li>\n\n\n\n<li><strong>Royalty Upside<\/strong>: <strong>Mid\u2011single\u2011digit to low\u2011double\u2011digit royalties<\/strong> on potential <strong>blockbuster programs<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Platform<\/th><th>Focus<\/th><th>Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>Cartography + Pfizer<\/strong><\/td><td>ATLAS\/SUMMIT<\/td><td>Tumor antigens<\/td><td>Discovery to clinical<\/td><\/tr><tr><td><strong>Surface Oncology<\/strong><\/td><td>Target discovery<\/td><td>Immuno\u2011oncology<\/td><td>Clinical<\/td><\/tr><tr><td><strong>PACT Pharma<\/strong><\/td><td>Neoantigen TCR<\/td><td>Cell therapy<\/td><td>Phase\u202fI\/II<\/td><\/tr><tr><td><strong>Immunocore<\/strong><\/td><td>TCR platform<\/td><td>Bispecifics<\/td><td>Marketed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>First\u2011Mover Advantage<\/strong>: Cartography\u2019s <strong>integrated discovery\u2011to\u2011validation<\/strong> platform is <strong>12\u201118 months ahead<\/strong> of next\u2011gen competitors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-structure-amp-milestones\">Financial Structure &amp; Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount<\/th><th>Trigger<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD\u202f20\u202fmillion<\/td><td>Agreement signing<\/td><\/tr><tr><td><strong>Near\u2011Term Milestones<\/strong><\/td><td>USD\u202f45\u202fmillion<\/td><td>Antigen nomination, validation<\/td><\/tr><tr><td><strong>Development Milestones<\/strong><\/td><td>~USD\u202f400\u202fmillion<\/td><td>IND filings, Phase\u202fI\u2011III<\/td><\/tr><tr><td><strong>Commercial Milestones<\/strong><\/td><td>~USD\u202f385\u202fmillion<\/td><td>Regulatory approvals, sales thresholds<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td><strong>USD\u202f850\u202fmillion<\/strong><\/td><td>Excluding royalties<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Mid\u2011single to low\u2011double\u2011digit %<\/td><td>Tiered on net sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Risk Sharing<\/strong>: Pfizer\u2019s <strong>opt\u2011in structure<\/strong> allows strategic flexibility; Cartography retains <strong>CBI\u20111214<\/strong> entirely.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding antigen discovery timelines, milestone achievements, and market potential for Pfizer\u2011Cartography collaboration programs. Actual results may differ materially due to clinical validation challenges, competitive dynamics, and regulatory acceptance of novel targets.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. (NYSE: PFE) and Cartography Biosciences, Inc. announced a strategic collaboration to discover tumor-selective&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53345,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[16,4540,863,309],"class_list":["post-53343","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-cancer","tag-cartography-biosciences","tag-nyse-pfe","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE: PFE) and Cartography Biosciences, Inc. announced a strategic collaboration to discover tumor-selective antigens using Cartography\u2019s proprietary ATLAS and SUMMIT platforms. Under the multi-year agreement, Pfizer may opt in on validated antigens and will lead all research, development, and commercialization. The deal, valued at up to USD\u202f850\u202fmillion, includes USD\u202f65\u202fmillion in upfront and near-term payments plus tiered royalties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53343\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE: PFE) and Cartography Biosciences, Inc. announced a strategic collaboration to discover tumor-selective antigens using Cartography\u2019s proprietary ATLAS and SUMMIT platforms. Under the multi-year agreement, Pfizer may opt in on validated antigens and will lead all research, development, and commercialization. The deal, valued at up to USD\u202f850\u202fmillion, includes USD\u202f65\u202fmillion in upfront and near-term payments plus tiered royalties.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53343\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-08T05:53:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-08T05:53:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0801.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53343#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53343\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal\",\"datePublished\":\"2026-01-08T05:53:30+00:00\",\"dateModified\":\"2026-01-08T05:53:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53343\"},\"wordCount\":525,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53343#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0801.webp\",\"keywords\":[\"Cancer\",\"Cartography Biosciences\",\"NYSE: PFE\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53343#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53343\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53343\",\"name\":\"Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53343#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53343#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0801.webp\",\"datePublished\":\"2026-01-08T05:53:30+00:00\",\"dateModified\":\"2026-01-08T05:53:31+00:00\",\"description\":\"Pfizer Inc. (NYSE: PFE) and Cartography Biosciences, Inc. announced a strategic collaboration to discover tumor-selective antigens using Cartography\u2019s proprietary ATLAS and SUMMIT platforms. Under the multi-year agreement, Pfizer may opt in on validated antigens and will lead all research, development, and commercialization. The deal, valued at up to USD\u202f850\u202fmillion, includes USD\u202f65\u202fmillion in upfront and near-term payments plus tiered royalties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53343#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53343\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53343#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0801.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0801.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53343#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer Inc. (NYSE: PFE) and Cartography Biosciences, Inc. announced a strategic collaboration to discover tumor-selective antigens using Cartography\u2019s proprietary ATLAS and SUMMIT platforms. Under the multi-year agreement, Pfizer may opt in on validated antigens and will lead all research, development, and commercialization. The deal, valued at up to USD\u202f850\u202fmillion, includes USD\u202f65\u202fmillion in upfront and near-term payments plus tiered royalties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53343","og_locale":"en_US","og_type":"article","og_title":"Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal","og_description":"Pfizer Inc. (NYSE: PFE) and Cartography Biosciences, Inc. announced a strategic collaboration to discover tumor-selective antigens using Cartography\u2019s proprietary ATLAS and SUMMIT platforms. Under the multi-year agreement, Pfizer may opt in on validated antigens and will lead all research, development, and commercialization. The deal, valued at up to USD\u202f850\u202fmillion, includes USD\u202f65\u202fmillion in upfront and near-term payments plus tiered royalties.","og_url":"https:\/\/flcube.com\/?p=53343","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-08T05:53:30+00:00","article_modified_time":"2026-01-08T05:53:31+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0801.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53343#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53343"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal","datePublished":"2026-01-08T05:53:30+00:00","dateModified":"2026-01-08T05:53:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53343"},"wordCount":525,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53343#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0801.webp","keywords":["Cancer","Cartography Biosciences","NYSE: PFE","Pfizer"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53343#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53343","url":"https:\/\/flcube.com\/?p=53343","name":"Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53343#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53343#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0801.webp","datePublished":"2026-01-08T05:53:30+00:00","dateModified":"2026-01-08T05:53:31+00:00","description":"Pfizer Inc. (NYSE: PFE) and Cartography Biosciences, Inc. announced a strategic collaboration to discover tumor-selective antigens using Cartography\u2019s proprietary ATLAS and SUMMIT platforms. Under the multi-year agreement, Pfizer may opt in on validated antigens and will lead all research, development, and commercialization. The deal, valued at up to USD\u202f850\u202fmillion, includes USD\u202f65\u202fmillion in upfront and near-term payments plus tiered royalties.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53343#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53343"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53343#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0801.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0801.webp","width":1080,"height":608,"caption":"Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53343#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0801.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53343","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53343"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53343\/revisions"}],"predecessor-version":[{"id":53346,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53343\/revisions\/53346"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53345"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53343"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53343"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}